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A B S T R A C TObjective: Atrial fibrillation (AF) is an important risk factor for stroke.
The primary purpose of this study was to estimate the 1-year direct
and indirect costs of ischemic stroke in Chinese patients with AF.
Method: A total of 300 charts were selected and reviewed in 18
hospitals from neurology departments in six major cities of China
nationwide. Patients with primary diagnosis of ischemic stroke and
secondary diagnosis of AF were selected for review. A total of 63
patients were selected from the chart review pool and followed up for 1
year to record their resource utilization and absenteeism from work
following discharge. Results: The mean  SD age of the cohort was
70.2  11.8 years, with an average hospitalization duration of stay of
17.9 days. The mean total direct cost for AF-related stroke was
estimated at 30,438.3 China Yuan (CNY) per patient-year. The major
cost driver for direct cost was stroke’s acute hospitalization expense,
which accounted for 61.5% (CNY 18,706.1). Among the seven patients
not reaching the legal retirement age, the indirect cost per person-yearsee front matter Copyright & 2013, International
r Inc.
.1016/j.vhri.2013.02.008
st: The authors have indicated that they have no
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ondence to: Shanlian Hu, School of Public Health, Futotaled 16,838.9 CNY, most of which (63.0%) was a result of early
retirement. The analysis also suggested that higher hospital ranking
(based on the tier system), longer hospital stay, higher modified Rankin
Scale score, taking surgery during hospitalization, receiving thrombol-
ysis therapy, and incidence of complications such as pneumonia or
cerebral edema predicted higher inpatient costs. Conclusions: Hospi-
tal costs due to strokes among patients with AF are the predominant
contributor to the total direct cost, which is consistent with current
hospital-centered treatment pattern in China. However, literature
suggested that AF-induced strokes are highly preventable with drugs
and clinical procedures, which highlights the importance of optimal
clinical management of stroke prevention in patients with AF.
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Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In China, stroke-related clinical and economic burden is sig-
nificant: as part of the MONICA project, the standardized
incidence of acute stroke showed an average annual increase
of 5.2% in ischemic stroke, and an average annual decline of
3.6% in intracerebral hemorrhage from 1984 to 1999 in the
population aged 25 to 74 years in Beijing [1,2]. In 1984, the
standardized incidence rate of total stroke, intracerebral hem-
orrhagic stroke, and ischemic stroke in this population was
268.4, 109.5, and 139.3 per 100,000, respectively, while in 1999,
this rate reached 364.1, 59.5, and 295.7 per 100,000, respectively,
with the majority of stroke being ischemic stroke [3]. The
average cost for ischemic stroke treatment in municipal-level
or higher hospitals increased from China Yuan (CNY) 8798.8 in
2004 to CNY 11807.0 in 2011 [4] (Fig. 1). It has been suggested inthe literature that atrial fibrillation (AF)-related stroke drives up
the cost for total stroke treatment: a German study suggested
that AF-related strokes cost h11,799 versus h8817 for non–AF-
related strokes (P o 0.001) [5]. In China, however, no study so far
has addressed the burden of AF-related ischemic stroke. With
the lack of AF-related stroke cost data, any future economic
evaluations could potentially underestimate the true cost of AF-
related stroke, resulting in biases in future cost-effectiveness
analysis of any innovative pharmacological and nonpharmaco-
logical clinical therapies in preventing strokes in patients with
AF. The primary objective of the present study was to estimate
the short-term and long-term medical resource use (within
a year) for patients admitted to a hospital with acute is-
chemic stroke and to calculate total direct costs for patients
with AF-related stroke, supplemented with labor-force–related
indirect costs.Society for Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Percentage of direct-cost components.
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Study Design and Patient Selection
This was a retrospective cross-sectional nonrandomized
hospital-based cost-of-illness chart review study from societal
perspective. The study was carried out in 18 hospitals from six
cities (Beijing, Shanghai, Guangzhou, Chengdu, Shenyang, and
Hangzhou) nationwide in China, 12 of which are tier-3 hospitals
(Peking University Third Hospital, Beijing Shijitan Hospital, Bei-
jing Tiantan Hospital, Shanghai Renji Hospital, Shanghai Tenth
People’s Hospital, Changhai Hospital, Guangzhou First Municipal
People’s Hospital, First Affiliated Hospital of Jinan University, The
First Hospital of China Medical University, The Second Hospital of
China Medical University, Huaxi Hospital, and The Second Affili-
ated Hospital of Zhejiang University School of Medicine) while
the other 6 are tier-2 hospitals (Chuiyangliu Hospital, Shanghai
First People’s Hospital Branch, Zengcheng People’s Hospital, the
Fourth People’s Hospital of Shenyang, Chengdu Nuclear Industry
416 Hospital, and Hangzhou Red Cross Hospital). A total of 300
available charts from neurology departments of the above hos-
pitals from 2010 to 2011 were selected and reviewed. The
selection inclusion criteria were patients’ time of discharge being
between January 1, 2010, and December 31, 2011, with primary
discharge diagnosis being ischemic stroke and secondary dis-
charge diagnosis being AF (including all subtypes of AF with
various severities). The exclusion criteria were patients’discharge
diagnosis being transient ischemic attack, death during in-
patient period, and patient discharge against medical advice. A
total of 63 patients, who were willing to participate in the follow-
up survey, were selected from the chart review pool and followed
up 1-year postdischarge to assess their resource utilization and
absenteeism from work. Among the 18 hospitals, Shanghai No.
Ten People’s Hospital refused to take part in the follow-up survey
because of administration difficulties, and so no patient from
Shanghai No. Ten People’s Hospital was included in the follow-up
phase. All costs in this article are expressed in 2010 CNY with no
discount rate applied.Data Collection
Data were collected by physicians through chart review and
patient interview via two sets of questionnaire. The chart review
questionnaire captured the patients’ sociodemographic charac-
teristics, number of hospitalization days, medical history, life-
style, stroke, AF and type, reimbursement status and insurancetype, National Institutes of Health Stroke Scale score, modified
Rankin Scale (mRS) score, CHA2DS2-VASc score, treatment pat-
tern, categorized cost during hospitalization, as well as compli-
cation occurrence. The above information was abstracted from
patients’ charts and could reflect the patients’ status at admis-
sion. All costs incurred during hospitalization were grouped into
one of seven cost centers: pharmacy, imaging, laboratory, diag-
nosis, procedure, nursing, and others. The follow-up question-
naire focused on stroke-related resource utilization, patient and
family absenteeism from work, as well as early retirement due to
stroke during the 1-year period following the discharge.
Direct Cost Estimate
Direct costs measure the opportunity cost of resources used for
treating a particular illness [6,7].
In this study, patients’ medical records were reviewed to elicit
all medical health care resources consumed during stroke acute
hospitalization stage and patient follow-up surveys were con-
ducted to collect resource utilization during 1 year following
discharge. Direct costs collected included direct medical cost and
a small part of nonmedical cost. The former consisted of
diagnostic test, clinical treatment, radiological exam, laboratory
exam, rehabilitation, medication, in- and outpatient service, and
nursing care at home and hospital. Complication management
costs have been accounted for and included in the cost categories
mentioned above. The nonmedical costs consisted of patients’
out-of-pocket costs such as stroke treatment or rehabilitation-
related traffic costs.
Indirect Cost Estimate
Indirect costs represent productivity losses due to impairment of
work capacity and/or daily activities [3]. The human capital
approach was used to calculate indirect costs [8]. The human
capital approach measures lost production, in terms of lost
earnings, of a patient or caregiver, using wages as a proxy
measure of the output of work time [9–11]. It often includes the
value of household work, valued as the opportunity cost of hiring
a replacement from the labor market. In our study, patients were
asked whether they or their family member got early retirement
or absenteeism due to stroke. The total number of days was
counted, and indirect costs (productivity loss of the labor-force
participants) were calculated by multiplying days off work or
days of early retirement with the average cost factor per day.
Wages were derived from Wage and Payroll statistics for workers
in the post of nonprivate institutions in cities and towns in 2010,
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101.77).
Statistical Analyses
Statistical analyses were performed by using the Statistics Package
for Social Sciences (STATA Special Edition, version 12.0; StataCorp,
College Station, TX). Descriptive statistics were used for demo-
graphic and clinical variables, use of health care resources, and
costs including frequencies, percentage, means and SD, and
median. Multiple linear regression analysis was performed to
determine predictors of increased hospitalization costs. Independ-
ent variables included city, hospital tier, thrombolysis or no
thrombolysis, having or not having complications such as pneu-
monia and cerebral edema, hospitalization duration, CHA2DS2-
VASc score, mRS score, taking or not taking surgery, and receiving
or not receiving defibrase therapy. Because of the skewed distribu-
tion of cost, the dependent variable in our regression analyses was
log transformed.Results
Patient Characteristics
The main characteristics of the total of 300 patients recruited for
chart review are shown in Table 1. The mean  SD age of the
cohort was 70.2  11.8 years, and the majority were retired
(77.7%); 57.3% of them were men. The cohort had a mean  SD
hospitalization duration of 17.9  9.6 days. Average National
Institutes of Health Stroke Scale score was 8.3  6.2, average
mRS score was 3.0  1.4, and average CHA2DS2-VASc score wasTable 1 – Baseline sociodemographic and clinical
characteristics (n ¼ 300).
Mean  SD
Age (y) 70.2  11.8
Women, n (%) 128 (42.7)
Retired, n (%) 233 (84.4)
Hospitalization (d) 17.9  9.6
NIHSS score (points) 8.3  6.2
mRS score (points) 3.0  1.4
CHA2DS2-VASc score (points) 3.0  1.8
Stroke classification, n (%)
TACI 18 (6)
PACI 216 (72)
POCI 45 (15)
LACI 5 (1.7)
Other 16 (5.3)
AF type, n (%)
Paroxysmal 38 (12.7)
Persistent 42 (14)
Permanent 28 (9.3)
Unspecified 192 (64)
Valvular 24 (8)
Nonvalvular 79 (26.3)
Unspecified 197 (65.7)
AF history (y) 5.8 (8.0)
LACI, lacunar infarct; mRS, modified Rankin Scale; NIHSS, National
Institutes of Health Stroke Scale; PACI, partial anterior circulation
infarct; POCI, posterior circulation infarct; TACI, total anterior
circulation infarct.
 Results are presented as mean  SD, unless otherwise
mentioned.3.0  1.8. All patients had major discharge diagnosis of ischemic
stroke, with total anterior circulation infarct accounting for 6%.
partial anterior circulation infarct 72%, posterior circulation
infarct 15%, and lacunar infarct 1.7%, as well as AF on charts as
secondary diagnosis. A total of 83.3% of the patients had certain
type of insurance, ranging from basic medical insurance (67.3%)
to new rural cooperative medical insurance (7%) to free medical
care (9%). Patient characteristics of the 63 follow-up patients are
reported in Table 2.
Resource Use and Costs
Resource utilization for both inpatient stage and 1 year after
discharge is presented in detail in Table 3. The average total direct
cost for AF-related stroke was estimated at 30,438.3 CNY per
patient-year, among which AF treatment cost accounted for 0.3%,
totaling 98.7 CNY per patient-year. The major cost driver for direct
cost was stroke’s acute hospitalization expense, which accounted
for 61.5% (CNY 18,706.1), followed by drug consumption during 1-
year follow-up, which accounted for 21.1% (CNY 6,436.4). Please
refer to Fig. 2 for detailed breakdown for direct cost. Only four
patients incurred nonmedical cost. In the follow-up group, among
the seven patients not reaching the legal retirement age (60 years
for men, 55 years for women), the indirect cost per person-year
totaled 16,838.9 CNY, most of which (63.0%) was incurred by early
retirement, while financial loss due to patient and family absence
from work accounted for 31.5% and 5.5%, respectively.
Association between demographic, clinical variables, and
hospitalization cost was assessed by using multivariate regres-
sion analysis (Table 4). Holding other variables constant, inpa-
tient cost was significantly lower in Shenyang than in
Guangzhou, while there was no significant difference comparingTable 2 – Baseline sociodemographic and clinical
characteristics (n ¼ 63).
Mean  SD
Age (y) 69.9  10.3)
Women, n (%) 32 (50.8)
Retired, n (%) 56 (88.9)
Hospitalization (d) 17.0  9.4
NIHSS score (points) 8.1  5.6
mRS score (points) 2.9  1.3
CHA2DS2-VASc score (points) 3.2  1.8
Stroke classification, n (%)
TACI 2 (3.2)
PACI 41 (65.1)
POCI 7 (11.1)
LACI 3 (4.8)
Other 10 (15.9)
AF type, n (%)
Paroxysmal 13 (20.6)
Persistent 3 (4.8)
Permanent 3 (4.8)
Unspecified 44 (69.8)
Valvular 10 (15.9)
Nonvalvular 16 (25.4)
Unspecified 37 (58.7)
AF history (y) 7 (9.8)
LACI, lacunar infarct; mRS, modified Rankin Scale; NIHSS, National
Institutes of Health Stroke Scale; PACI, partial anterior circulation
infarct; POCI, posterior circulation infarct; TACI, total anterior
circulation infarct.
 Results are presented as mean  SD, unless otherwise
mentioned.
Table 3 – Direct cost breakdown (consisting of costs incurred during acute hospitalization and 1 y after
discharge).
Cost category Mean  SD (CNY) Percentage of direct cost (%) Percentage of indirect cost (%)
Direct cost 30,438.3
Acute hospitalization 18,706.1  15,116.3 61.5
Diagnostic exam 464.3  1,037.1 1.5
Clinical treatment 1,626.2  3,330.2 5.3
Nursing 332.1  454.7 1.1
Medication 10,238.1  9279.0 33.6
Laboratory examination 1766.3  1,295.7 5.8
Radiological examination 2217.9  1,481.3 7.3
1 y after discharge 11,732.2  14271.0 38.5
Medication 6,436.4  6435.3 21.1
Radiological examination 760.6  2573.0 2.5
Laboratory examination 573.7  747.3 1.9
Clinical treatment 108.9  196.3 0.4
Rehabilitation 689.6  3455.9 2.3
Nursing care 2,971.0  7435.9 9.8
Transportation 126.5  235.5 0.4
CNY, China Yuan.
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hou, respectively. As Table 5 indicated, higher hospital tier ranking,
longer hospital stay, higher mRS score, taking surgery, receiving
thrombolysis therapy, and having complications such as pneumo-
nia or cerebral edema predicted higher inpatient costs.Clinical Treatment Pattern
For AF-related ischemic stroke in-patient management, standard
warfarin therapy was used in 27.3% of the total 300 patients,
while aspirin was prescribed to 62.3% of the patients. As far as
newer agents were concerned, 21.3% of the patients took clopi-
dogrel, while 3.7% of the patients took ozagrel.Discussion
The results of the present study, conducted at 18 Chinese
hospitals located in six cities nationwide with patient- and/or
caregiver-reported feedback, showed that the direct and indirect
costs of stroke management were considerable during the acute
hospitalization stage and the 12-month period after discharge.
The largest contributors to the total direct costs were initial
hospital stay (61.5%) and drug consumption during 1 year after
discharge (21.2%), while those to indirect costs were patients’
early retirement and patients’ absence from work, accounting for
63.0% and 31.5%, respectively.0
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Fig. 2 – Inpatient cost for ischemic stroke among hospitalsComparison with Other Studies
According to Shanlian Hu [12], the mean hospitalization cost of
patients with ischemic stroke in China was CNY 10,489 in 2000
for average 18 hospitalization days, with medication accounting
for 37.7% (CNY 3,959, year 2000). Our study results indicated that
hospitalization cost averaged CNY 18,706.1 for average 17.9
inpatient days, with medication accounting for 54.7% (CNY
10,238, 2010). Considering the impact of inflation (2000 CNY
10,489 ¼ 2010 CNY 12,962.13), the hospitalization cost was still
much higher than that of 2000, which was mainly boosted by the
extensive use of innovative drugs and clinical diagnostic and
treatment procedures. During the past few years, new therapies
such as thrombolysis for ischemic stroke treatment have been
gradually accepted nationwide. Our study results showed that
thrombolysis therapy is widely used in the survey hospitals,
exerting a significant influence on hospitalization cost even after
adjustment for factors such as region, hospital tier, complication
of pneumonia and cerebral edema, inpatient days, surgery,
defibrase therapy adoption, and mRS and CHADS2-VAS scores
(Table 4).
According to Bru¨ggenju¨rgen et al. [5], direct cost of AF-related
stroke per patient-year in Germany was h11,799.1 (exchange rate:
h1 ¼ $1.32 [January 2005]), while our result indicated it being CNY
30,438.3. Acute hospitalization costs were the biggest component
of direct cost for both studies, accounting for 61.5% in China and
46% in Germany. Considering the inflation and exchange rate, the
direct cost was much higher in Germany than in China.2008 2009 2010 2011
ospitalization Cost
of municipal level or upward (CNY). CNY, China Yuan.
Table 4 – Multivariate analysis for predictors of
inpatient costs (linear regression of log10 hospita-
lization costs; R2 ¼ 0.832).
Independents Coefficient P
Region: Beijing .021 0.800
Region: Shanghai .085 0.495
Region: Shenyang .216 0.003
Hospital tier .264 0.001
Log10 hospitalization days .731 0.000
CHA2DS2-VASc score .027 0.082
mRS score .064 0.014
Defibrase therapy or not .352 0.067
Surgery or not .665 0.000
Thrombolysis or not .261 0.030
Complication: Cerebral edema .429 0.008
Complication: Pneumonia or not .290 0.000
Reference city for region as an independent variable: Guangzhou.
yPo 0.05 is considered statistically significant.
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aspects: first, because of the limitation associated with chart
review methodology, some of the acute treatment costs for stroke
incurred in emergency room might not be captured. Second,
Chinese patients with stroke invested much less in rehabilitation
than did their German counterparts: CNY 689.6 accounting for
2.3% of the total direct cost versus h1699, accounting for 14% of
the total direct cost. Third, nursing care cost in our study was
CNY 2971, accounting for 9.8% of the direct cost. This proportion
was similar to the German counterpart, which was 10%. The
expense on this could be underestimated in that nursing care in
our study included nursing care at home only; however, the
human/labor costs related to nursing are much higher for
Germany than for China. Fourth, medical service expense, that
is, hospital visiting professional fee, accounted for a tiny part in
the direct cost in China compared with the West [1].
As far as direct cost was concerned, however, in one arena
Chinese patients incurred higher costs than their German coun-
terparts, which was medication. Chinese ischemic stroke
patients with AF spent much more on medication during 1 year
after hospital discharge than did their counterparts in the West:
CNY 6,436.4 versus h829, accounting for 21.1% and 7% of the total
direct cost, respectively [1].
Comparison of Direct and Indirect Costs
Direct cost dominated the burden for AF-related stroke in China.
First, the direct cost of AF-related stroke was CNY 30,438.3, while
the indirect cost was CNY 16,839, accounting for 64.4% and 35.6%
of the total cost, respectively. Second, most of the patients (56 ofTable 5 – Indirect cost breakdown.
Cost category Mean  SD
(CNY)
Percentage of
indirect cost (%)
Indirect cost (n ¼ 7) 16,839
Early retirement 10,613.2 63.0
Patient
absenteeism
from work
5,306.6 31.5
Family
absenteeism
from work
919.2 5.5
CNY, China Yuan.63) participating in the follow-up survey had retired, not able to
incur indirect cost. This is consistent with literature findings:
stroke risk increases with age in patients who have nonvalvular
AF [13]. The prevalence of AF increases with patient age [14]. In
China, the prevalence rate of AF in the patient group aged
between 80 and 90 years was 7.5%, which was significantly higher
than that of any other age group [15]. Also, AF independently
increased stroke risk fivefold; this was especially true in aged
population. With increasing age, the effects of hypertension,
coronary heart disease, and cardiac failure on the risk of stroke
became progressively weaker (Po 0.05). Advancing age, however,
did not reduce the significant impact of AF. For persons aged 80 to
89 years, AF was the sole cardiovascular condition to exert an
independent effect on stroke incidence (P o 0.001). The attribut-
able risk of stroke for all cardiovascular contributors decreased
with age except for AF, for which the attributable risk increased
significantly (P o 0.01), rising from 1.5% for those aged 50 to 59
years to 23.5% for those aged 80 to 89 years [16]. So, the influence
of AF on stroke risk increases sharply with age.
Impact of Costs on Patients’ Affordability in China
China is in the midst of health care reform with the aim to
provide universal coverage to more than 95% of the population. In
our study, the hospitals included were tier 2 and above, where
most patients had some type of insurance coverage. With
experience suggesting that lower-tier hospitals do likely cover
patients with no health care insurance and our multivariate
analysis indicating that higher-tier hospitals were associated
with higher total management costs, there was an indication
that the insurance status/affordability could impact patients’
care-seeking behaviors.
Limitations
First, selection bias in the follow-up survey was inevitable,
leading to underestimation of stroke burden [1]. That was
because patients willing to take the follow-up survey were in
much better health condition than those not in terms of initial
stroke severity and rehabilitation afterwards. Given that more
severe strokes tend to be more costly [17], the costs presented in
this study were conservative and might be underestimated.
Another important consideration was that we studied only
those patients who were alive after 12 months. We had no
information as to resource use for those who died within 12
months of the stroke event. Those having died during the last 12
months might have consumed more inpatient costs during their
end-of-life stage care.
We relied on patient and/or caregiver’s recall of resource
consumption during 12 months after hospitalization, which
might have also introduced a bias toward underreporting; how-
ever, the key cost drivers were acute hospitalization (accounting
for 61.5% of total direct costs), the data for which were provided
empirically via patient records [1].
Last, we relied on the inclusion of follow-up patients from the
chart review pool to improve the consistency and generalizabil-
ity; however, collection and reporting of acute hospitalization
cost among 63 follow-up patients and comparing it with that of
300 patients enrolled for chart review could better ensure that the
results from the 300 patients were generalizable to the 63
patients for their acute hospitalization costs.Conclusions
The study findings indicated that AF-related ischemic stroke
imposed considerable clinical and economic burden on society
in China. Hospital costs were the predominant contributor,
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patient care is usually provided via hospitals. With increased
evidence suggesting that AF-induced strokes are preventable
with innovative drugs and medical treatment procedures, it
highlights the importance of optimal clinical management of
stroke prevention in patients with AF.Acknowledgments
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